{
    "guideline_identifier": "PIIS092375342204769X.txt",
    "cancer_focus": {
        "primary_cancer": "Cancer of Unknown Primary",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Oligometastatic",
            "treatment_plans": [
                {
                    "clinical_context": "Oligometastatic disease amenable to local ablation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Local ablative therapy (surgery/radiotherapy) if feasible. Pre-treatment requires FDG-PET/CT + brain MRI to exclude additional metastases.",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Breast-like",
            "treatment_plans": [
                {
                    "clinical_context": "Women with isolated axillary lymph node involvement",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Axillary lymph node dissection + breast radiotherapy or mastectomy. Systemic therapy aligned with breast cancer guidelines.",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "ER",
                            "status": "Tested",
                            "testing_guidance": "Required for therapy selection"
                        },
                        {
                            "name": "PgR",
                            "status": "Tested",
                            "testing_guidance": "Required for therapy selection"
                        },
                        {
                            "name": "HER2",
                            "status": "Tested",
                            "testing_guidance": "Required for therapy selection"
                        }
                    ],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Ovary-like",
            "treatment_plans": [
                {
                    "clinical_context": "Women with peritoneal carcinomatosis",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgical debulking + carboplatin/paclitaxel ± bevacizumab. PARP inhibitors if BRCA1/2 mutant.",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1/2",
                            "status": "Mutant",
                            "testing_guidance": "Germline testing recommended"
                        }
                    ],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Head/Neck-like",
            "treatment_plans": [
                {
                    "clinical_context": "Squamous cell carcinoma in cervical lymph nodes",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neck dissection ± radiotherapy/chemotherapy.",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "p16/HPV",
                            "status": "Tested",
                            "testing_guidance": "Required for diagnosis"
                        },
                        {
                            "name": "EBV",
                            "status": "Tested",
                            "testing_guidance": "Required for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Colon-like",
            "treatment_plans": [
                {
                    "clinical_context": "Adenocarcinoma with colorectal IHC profile (CK7–/CK20+/CDX2+)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOX/FOLFIRI ± bevacizumab (MSS) or immunotherapy (MSI-H/dMMR).",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "MSI/dMMR",
                            "status": "High",
                            "testing_guidance": "Test all cases"
                        }
                    ],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Prostate-like",
            "treatment_plans": [
                {
                    "clinical_context": "Men with blastic bone metastases + PSA expression",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Androgen deprivation therapy per prostate cancer guidelines.",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "PSA",
                            "status": "Expressed",
                            "testing_guidance": "Required for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Favourable Subtypes",
            "risk_group": "Renal-like",
            "treatment_plans": [
                {
                    "clinical_context": "Carcinoma with renal cell IHC profile",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "TKI/ICI therapy per renal cell carcinoma guidelines.",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                }
            ]
        },
        {
            "staging_criteria": "Unfavourable Subtypes",
            "risk_group": "Good Prognosis (ECOG PS 0–1 + normal LDH)",
            "treatment_plans": [
                {
                    "clinical_context": "Fit patients without favourable subtype features",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum-based doublets (cisplatin/gemcitabine or carboplatin/paclitaxel). Avoid triplet regimens due to toxicity.",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III-B"
                },
                {
                    "clinical_context": "NTRK fusion-positive",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Larotrectinib or entrectinib (tumor-agnostic approval).",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "NTRK",
                            "status": "Fusion",
                            "testing_guidance": "NGS recommended"
                        }
                    ],
                    "esmo_evidence_level": "III-A"
                },
                {
                    "clinical_context": "EGFR/ALK/ROS1 alterations (NSCLC suspected)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Tyrosine kinase inhibitors.",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "EGFR/ALK/ROS1",
                            "status": "Altered",
                            "testing_guidance": "Test if NSCLC suspected"
                        }
                    ],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "BRAF V600E mutation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "BRAF inhibitors (especially if lung primary suspected).",
                    "treatment_line": "",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF",
                            "status": "V600E mutation",
                            "testing_guidance": "Test if lung primary suspected"
                        }
                    ],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "MSI-H/dMMR (non-colon-like)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab.",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "MSI/dMMR",
                            "status": "High",
                            "testing_guidance": "Test all cases"
                        }
                    ],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "TMB-high (≥10 mut/Mb)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Consider nivolumab or pembrolizumab.",
                    "treatment_line": "Relapsed/refractory",
                    "biomarker_requirements": [
                        {
                            "name": "TMB",
                            "status": "High (≥10 mut/Mb)",
                            "testing_guidance": "Test when considering immunotherapy"
                        }
                    ],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "PD-L1-high",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Consider immune checkpoint inhibitors.",
                    "treatment_line": "Relapsed/refractory",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "High",
                            "testing_guidance": "Test when considering immunotherapy"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Unfavourable Subtypes",
            "risk_group": "Poor Prognosis (ECOG PS ≥2 or elevated LDH)",
            "treatment_plans": []
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Biomarkers determine favourable subtypes, guide site-specific therapies, predict response to targeted treatments (e.g., NTRK inhibitors, PARP inhibitors) and immunotherapy (e.g., MSI-H/dMMR, TMB-high), and inform prognosis."
    }
}